Minerva Neurosciences reported $-9205000 in Pre-Tax Profit for its third fiscal quarter of 2021.


Ok
Trading Economics members can view, download and compare data from nearly 200 countries, including more than 20 million economic indicators, exchange rates, government bond yields, stock indexes and commodity prices.

The Trading Economics Application Programming Interface (API) provides direct access to our data. It allows API clients to download millions of rows of historical data, to query our real-time economic calendar, subscribe to updates and receive quotes for currencies, commodities, stocks and bonds.

Please Paste this Code in your Website
width
height
Pre Tax Profit Change
Acadia Pharmaceuticals ACAD:US $ -14.79M 28.61M
Adma Biologics ADMA:US $ -17.71M 0.39M
Arena Pharmaceuticals ARNA:US $ -126.31M 19.78M
AstraZeneca AZN:LN 1954M 415M
Bristol Myers Squibb BMY:US $ 5289M 67M
Eli Lilly And LLY:US $ 1470.5M 518.1M
Esperion Therapeutics ESPR:US $ -69386000 25.72M
Halozyme Therapeutics HALO:US $ 74.11M 17.41M
IONIS PHARMACEUT IONS:US $ -84M 3M
Johnson & Johnson JNJ:US $ 8058M 282M
Kindred Biosciences KIN:US $ -9.13M 0.61M
Marinus Pharmaceuticals MRNS:US $ -19.51M 4.32M
Minerva Neurosciences NERV:US $ -9.2M 1.38M
Neurocrine Biosciences NBIX:US $ 30.5M 27M
Novartis NOVN:VX SF 4544M 120M
Novavax NVAX:US $ -316.39M 32.38M
Takeda 4502:JP Y 61447M 161531M
Vanda Pharmaceuticals VNDA:US $ 10.72M 1.88M